

# Arti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/80643/publications.pdf>

Version: 2024-02-01

33  
papers

1,760  
citations

758635

12  
h-index

454577

30  
g-index

37  
all docs

37  
docs citations

37  
times ranked

3300  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Review on Pathophysiological Aspects of Sleep Deprivation. CNS and Neurological Disorders - Drug Targets, 2023, 22, 1194-1208.	0.8	5
2	Understanding the Role of Histone Deacetylase and their Inhibitors in Neurodegenerative Disorders: Current Targets and Future Perspective. Current Neuropharmacology, 2022, 20, 158-178.	1.4	55
3	Lipopolysaccharide induced altered signaling pathways in various neurological disorders. Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395, 285-294.	1.4	15
4	Inhalation potential of N-Acetylcysteine loaded PLGA nanoparticles for the management of tuberculosis: In vitro lung deposition and efficacy studies. Current Research in Pharmacology and Drug Discovery, 2022, 3, 100084.	1.7	15
5	Quercetin ameliorates lipopolysaccharide-induced neuroinflammation and oxidative stress in adult zebrafish. Molecular Biology Reports, 2022, 49, 3247-3258.	1.0	12
6	A review on recent advances in nanomedicines for the treatment of pulmonary tuberculosis. Journal of Drug Delivery Science and Technology, 2022, 69, 103069.	1.4	12
7	A review on the neuroprotective effect of berberine against chemotherapy-induced cognitive impairment. Current Drug Targets, 2022, 23, .	1.0	0
8	Inhalation Potential of Rifampicin-Loaded Novel Metal-Organic Frameworks for Improved Lung Delivery: Physicochemical Characterization, <i>In Vitro</i> Aerosolization and Antimycobacterial Studies. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2022, 35, 259-268.	0.7	6
9	Exploring Therapeutic Potential of Atorvastatin Against Gram-positive and Gram-negative Bacteria: In silico, In vitro and In vivo Evidences. Infectious Disorders - Drug Targets, 2021, 20, 798-815.	0.4	1
10	Crosstalk between anticancer drugs and mitochondrial functions. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100047.	1.7	20
11	Withdrawal Notice: Involvement of the Gut-brain Axis in Neurological Disorders. CNS and Neurological Disorders - Drug Targets, 2021, 20, .	0.8	1
12	Impact of Nano-Formulations of Natural Compounds in the Management of Neuro degenerative Diseases. , 2021, , 178-207.		0
13	Importance of Zebrafish as an Efficient Research Model for the Screening of Novel Therapeutics in Neurological Disorders. CNS and Neurological Disorders - Drug Targets, 2021, 20, 145-157.	0.8	7
14	Antibacterial potential of selected phytomolecules: An experimental study. Microbiology and Immunology, 2021, 65, 325-332.	0.7	6
15	Effect of hydro-alcoholic extract of centella asiatica on streptozotocin induced memory dysfunction in adult zebrafish. Current Research in Behavioral Sciences, 2021, 2, 100059.	2.4	2
16	Selective estrogen receptor modulators Against Gram-positive and Gram-negative bacteria: an experimental study. Future Microbiology, 2021, 16, 987-1001.	1.0	2
17	Coenzyme Q10 a mitochondrial restorer for various brain disorders. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 2197-2222.	1.4	24
18	Galactosylated nanoconstructs of Berberine with enhanced Biopharmaceutical and cognitive potential: A preclinical evidence in Alzheimer's disease. Journal of Drug Delivery Science and Technology, 2021, 66, 102695.	1.4	3

#	ARTICLE	IF	CITATIONS
19	Repurposing of Auranofin Against Bacterial Infections: An In silico and In vitro Study. <i>Current Computer-Aided Drug Design</i> , 2021, 17, 687-701.	0.8	7
20	Zebrafish an experimental model of Huntington's disease: molecular aspects, therapeutic targets and current challenges. <i>Molecular Biology Reports</i> , 2021, 48, 8181-8194.	1.0	12
21	Targeting N17 domain as a potential therapeutic target for the treatment of Huntington disease: An opinion. <i>EXCLI Journal</i> , 2021, 20, 1086-1090.	0.5	1
22	Phytomolecules against bacterial biofilm and efflux pump: an <i>in silico</i> and <i>in vitro</i> study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, 38, 5500-5512.	2.0	18
23	Mitochondrial Dysfunction: a Potential Therapeutic Target to Treat Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2020, 57, 3075-3088.	1.9	68
24	Selective Estrogen Receptor Modulators (SERMs): Mechanistic Insights Against Microbial Infections. <i>Current Molecular Medicine</i> , 2020, 20, 102-115.	0.6	7
25	Neuropathic Pain models caused by damage to central or peripheral nervous system. <i>Pharmacological Reports</i> , 2018, 70, 206-216.	1.5	58
26	Role of Glutathione-S-transferases in neurological problems. <i>Expert Opinion on Therapeutic Patents</i> , 2017, 27, 299-309.	2.4	36
27	Comparative Analysis of Intrahippocampal Amyloid Beta (1-42) and Intracerebroventricular Streptozotocin Models of Alzheimer's Disease: Possible Behavioral, Biochemical, Mitochondrial, Cellular and Histopathological Evidences. , 2016, 06, .		14
28	Possible neuroprotective mechanisms of clove oil against icv-colchicine induced cognitive dysfunction. <i>Pharmacological Reports</i> , 2016, 68, 764-772.	1.5	23
29	P3-319: Minocycline modulates the neuroprotective effect of coenzyme q10 against amyloid beta 1-42 induced cognitive dysfunction in rats: Behavioral and biochemical evidence. , 2015, 11, P759-P759.		0
30	A review on mitochondrial restorative mechanism of antioxidants in Alzheimer's disease and other neurological conditions. <i>Frontiers in Pharmacology</i> , 2015, 6, 206.	1.6	109
31	Microglial Inhibitory Mechanism of Coenzyme Q10 Against A $\beta$ (1-42) Induced Cognitive Dysfunctions: Possible Behavioral, Biochemical, Cellular, and Histopathological Alterations. <i>Frontiers in Pharmacology</i> , 2015, 6, 268.	1.6	22
32	Novel potential for optimization of antitubercular therapy: Pulmonary delivery of rifampicin lipospheres. <i>Asian Journal of Pharmaceutical Sciences</i> , 2015, 10, 549-562.	4.3	17
33	A review on Alzheimer's disease pathophysiology and its management: an update. <i>Pharmacological Reports</i> , 2015, 67, 195-203.	1.5	1,181